BioCryst Secures Reimbursement for ORLADEYO Across Major European Countries

BioCryst Pharmaceuticals has secured reimbursement approval for ORLADEYO (berotralstat) in the Netherlands, following a positive recommendation from Zorginstituut Nederland. This approval extends national reimbursement across all major European countries, enabling patients aged 12 and older to access the first once-daily oral preventive therapy for hereditary angioedema (HAE) attacks. ORLADEYO works by inhibiting plasma kallikrein to prevent HAE attacks but is not indicated for treating acute attacks. The drug has been commercially available since European Commission authorization in April 2021 and is now available in over 30 countries. BioCryst's revenue has shown strong growth, and the company maintains a bullish outlook on ORLADEYO's market potential and accessibility in Europe. The company emphasizes continuing its mission to provide innovative treatments to as many HAE patients as possible, though ongoing safety monitoring remains essential.